AI assistant
SHIELD THERAPEUTICS PLC — Remuneration Information 2018
May 15, 2018
7914_dirs_2018-05-15_f3158074-7223-4e39-a2e0-8d3476989924.html
Remuneration Information
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 1956O
Shield Therapeutics PLC
15 May 2018
Shield Therapeutics plc
(the "Company")
Grant of share options
London, UK, 15 May 2018. Shield Therapeutics plc (LSE:STX), a commercial stage pharmaceutical company, with an initial focus on addressing iron deficiency, announces that on 14th May 2018 it granted share awards in the form of options over ordinary shares in the capital of the Company ("Ordinary Shares") under the Company's Retention and Performance Share Plan, Bonus Share Plan and Company Share Option Plan. The plans are designed to provide staff with rewards alongside increases in shareholder value, as well as provide the Company with a meaningful retention tool.
If specific performance targets are achieved the Retention and Performance Share Plan awards, exercisable at a price of 1.5p, vest on 31 December 2018 and 31 December 2020. The Bonus Share Plan awards, which have been issued in lieu of the normal cash bonus payments for achievements during 2017 and are also exercisable at 1.5p, will vest on 31 May 2019. The Company Share Option Plan has an exercise price of 25.5p per Ordinary Share and vests on 14 May 2021.
The Company has the capacity to issue up to 10% of its issued share capital in the form of Options. Following these grants the total number of Ordinary Shares outstanding under all existing share incentive scheme arrangements is now 6,476,459, representing 5.6% of the Company's issued share capital.
In accordance with the requirements of the EU Market Abuse Regulations the following options have been granted to PDMRs:
| Name | Option | Number of Ordinary Shares under Option | Vesting Date |
| Mark Sampson PDMR | Retention and Performance Share Plan | 135,000 | 31 December 2018 |
| Carl Sterritt CEO | Bonus Share Plan | 317,184 | 31 May 2019 |
| Mark Sampson PDMR | Bonus Share Plan | 162,000 | 31 May 2019 |
| Carl Sterritt CEO | Retention and Performance Share Plan | 970,867 | 31 December 2020 |
| Mark Sampson PDMR | Retention and Performance Share Plan | 364,500 | 31 December 2020 |
Notification and public disclosure of transactions by PDMRs and persons closely associated with them
Retention and Performance Share Plan
| 1. | Details of PDMR / person closely associated with them ("PCA") | |
| a) | Name | Carl Sterritt - Founder, Director and PDMR Mark Sampson - PDMR |
| 2. | Reason for the notification | |
| a) | Position / status | PDMRs |
| b) | Initial notification / amendment | Initial notification |
| 3. | Details of the issuer | |
| a) | Name | Shield Therapeutics plc |
| b) | LEI | 213800G74QWY15FC3W71 |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
| a) | Description of the financial instrument, type of instrument | Ordinary shares of 1.5p each. |
| b) | Identification code | GB00BYV81293 |
| c) | Nature of the transaction | Grant of options over ordinary shares under the Shield Therapeutics Retention Share Plan. |
| d) | Price(s) and volume(s) |
Exercise price: 1.5p Volumes: Carl Sterritt 970,867 Mark Sampson 499,500 |
| e) | Aggregated information - Volume - Price |
1,470,367 Exercise price: 1.5p |
| f) | Date of the transaction | 14th May 2018 |
| g) | Place of the transaction | Outside a trading venue |
Bonus Share Plan
| 1. | Details of PDMR / person closely associated with them ("PCA") | |
| a) | Name | Carl Sterritt - Director/PDMR Mark Sampson - PDMR |
| 2. | Reason for the notification | |
| a) | Position / status | PDMRs |
| b) | Initial notification / amendment | Initial notification |
| 3. | Details of the issuer | |
| a) | Name | Shield Therapeutics plc |
| b) | LEI | 213800G74QWY15FC3W71 |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
| a) | Description of the financial instrument, type of instrument | Ordinary shares of 1.5p each. |
| b) | Identification code | GB00BYV81293 |
| c) | Nature of the transaction | Grant of options over ordinary shares under the Shield Therapeutics Bonus Share Plan. |
| d) | Price(s) and volume(s) |
Exercise price: 1.5p Volumes: Carl Sterritt 317,184 Mark Sampson 162,000 |
| e) | Aggregated information - Volume - Price |
479,184 Exercise price: 1.5p |
| f) | Date of the transaction | 14th May 2018 |
| g) | Place of the transaction | Outside a trading venue |
-Ends-
For further information please contact:
Shield Therapeutics plc +44 (0)207 186 8500
Carl Sterritt, Chief Executive Officer
Karl Keegan, Interim Chief Financial Officer
Nominated Advisor and Joint Broker +44 (0)203 100 2222
Liberum Capital Limited
Christopher Britton/Steve Pearce
Joint Broker +44 (0)207 418 8900
Peel Hunt LLP
James Steel/Christopher Golden
Financial PR Advisor +44 (0)203 709 5700
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal
About Shield Therapeutics plc
Shield Therapeutics is a commercial stage pharmaceutical company, delivering innovative specialty pharmaceuticals to address patients' unmet medical needs. Our clear purpose is to help our patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru®, for the treatment of all adults with iron deficiency with or without anaemia which has exclusive IP rights until the mid-2030's. For more information please visit www.shieldtherapeutics.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHUVUBRWRAVAAR